Navigation Links
Ondine Biomedical CEO Carolyn Cross Appointed Treasurer of International Photodynamic Association
Date:6/4/2013

Vancouver, British Columbia (PRWEB) June 04, 2013

The International Photodynamic Association (IPA) has appointed Carolyn Cross, founder and CEO of Ondine Biomedical as incoming IPA Treasurer. She will be replacing Dr. Tayyaba Hasan, Professor of Dermatology Wellman Center of Photomedicine, Harvard University, and Board Member of the IPA, in this position. Carolyn Cross was recently the Plenary Session Speaker at the 2013 World Congress of the International Photodynamic Association in Seoul, South Korea, representing the field of work in Photodisinfection; also known as antimicrobial Photodynamic Therapy or aPDT. Ondine Biomedical is the global leader in the design and development of Photodisinfection based therapies, and is involved with all aspects of technology, product and clinical development through to commercialization of photodisinfection products.

“The IPA represents an extraordinary group of scientists and clinical researchers who are advancing the field of PDT around the world. It is an honour to serve this community and look forward to working with the newly appointed Secretary of the IPA, Professor Sam Eljamel, University of Dundee Scotland, who will be hosting the 2017 World Congress in Scotland," says Carolyn Cross upon her appointment.

Founded in 1986, the International Photodynamic Association was created to promote the study of diagnosis and treatment using light and photosensitisers, to disseminate such information to the members of the IPA, the medical community, and the general public. The IPA organizes an International Congress every two years to highlight leading research activities in the clinical and basic research aspects of PDT.

Carolyn Cross is the founder and CEO of Ondine Biomedical Inc. and has over 18 years direct experience working with early stage companies and has 25 years of experience with public market securities. Additionally, she currently serves on a number of Boards including the Canadian Foundation of Innovation (CFI), the International Photodynamic Association and the Faculty of Dentistry, McGill University. She is a Founding Member of the BC Women's Economic Advisory Council and the Ernst & Young Global Women in Business Advisory Council (GWBAC).

Earlier in her career, Carolyn Cross was portfolio manager, responsible for managing pension, pooled, mutual and private client funds as a Vice President with Royal Bank Investment Management Inc., the fund management arm of the Royal Bank of Canada. Carolyn Cross is a currently a member of the Women’s Presidents Organization, the International Women’s Forum, the Professional Women's Network, the Toronto Society of Financial Analysts, the Society for Canadian Women in Science and Technology, and the Association for Professionals In Infection Control and Epidemiology.

About Ondine Biomedical Inc.

Ondine is an incubator, developing non-antibiotic therapies based on Photodisinfection technology for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with USA Research and Development laboratories in Bothell, Washington and Minneapolis, Minnesota. Please visit the Company website at: http://www.ondinebio.com and Blog at: http://www.ondineblog.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

Read the full story at http://www.prweb.com/releases/CarolynCross/InternationalPhotodynamic/prweb10796873.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ondine's CEO Carolyn Cross to be a Plenary Session Speaker at 14th World Congress of International Photodynamic Association
2. Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections
3. Arteriocyte announces Launch of Compass Biomedical
4. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
5. Premier Biomedical CEO Interviewed by The Wall Street Transcript
6. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
7. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
8. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
9. Fourth Annual Bay Area Biomedical Device Conference: March 27th, 2013 at San Jose State University
10. Foundation for the NIH Announces Lurie Prize Recognizing Outstanding Achievement by a Young Biomedical Scientist
11. ABIA Hires Biomedical Executive, Serial Entrepreneur as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):